In an era where American leadership on the global stage has been redefined by bold, unapologetic negotiation, President Trump has proven himself a master of the art of the deal and using existing and creating new leverage. From renegotiating NAFTA into the USMCA in the first term, extracting concessions from China through targeted tariffs, to pressuring European allies on defense spending and trade imbalances, his administration has wielded trade policy like a precision tool. These efforts have not only protected American workers and industries but have also forced trading partners to reckon with decades of unfair practices.
Yet, one area gives pause: the push for a Most Favored Nation (MFN) clause in drug pricing.
Applying a form of price controls to pharmaceuticals risks undermining innovation, patient access, and the very economic strength he's fought to bolster.
Let's first celebrate what the president has gotten right in his two terms as President. His approach to trade has been a breath of fresh air in Washington long dominated by multilateral complacency.
Take the USMCA, for instance—a deal that modernized North American trade with stronger labor protections, digital trade rules, and intellectual property safeguards. By threatening to walk away from the table, he compelled Mexico and Canada to agree to terms that leveled the playing field for U.S. auto workers and farmers. Similarly, his Phase One trade agreement with China addressed chronic issues like intellectual property theft and forced technology transfers, backed by tariffs that brought Beijing to negotiations despite initial bluster. These aren't just wins on paper; they've reshaped global supply chains, encouraging reshoring and reducing America's vulnerability to foreign dependencies.
Even in thornier disputes, the president's pressure tactics have yielded results. His tariffs on steel and aluminum prompted the European Union to rethink its subsidies and trade surpluses, leading to tentative agreements on digital taxes and energy. The deals that were rolled out with nations across the globe will lead to fewer restrictions on American products and investments worth trillions shifting to the US. This is strategic leverage that has boosted U.S. exports in key sectors and created jobs at home. Critics decry it as disruptive, but the president's willingness to use trade as a cudgel to make deals with nations around the globe has restored respect for American economic power, proving that deals aren't made by playing nice but by playing smart.
However, extending this trade playbook to drug pricing via an MFN policy is where admiration turns to concern. The MFN model, which ties U.S. Medicare payments for certain drugs to the lowest prices offered in other developed countries, sounds appealing on the surface—who wouldn't want lower drug costs? But it ignores the fundamental differences between negotiating steel tariffs and lifesaving medications. Unlike commodities, pharmaceuticals are the product of immense risk and investment. The U.S. is the home of most global drug innovation, with American companies funding over half of worldwide R&D. Foreign governments, through price controls, indeed “freeload” on this system, paying pennies on the dollar while U.S. patients and insurers foot the bill.
Imposing MFN would effectively import those foreign price controls, slashing revenues for innovators. Pharmaceutical firms already operate on thin margins for breakthrough drugs, with most candidates failing in trials. Cut their U.S. returns, and investment dries up—analysts estimate MFN could reduce R&D spending by billions, delaying or derailing cures for diseases like Alzheimer's, diabetes, cancer and a range of rare diseases. We've seen this play out in Europe, where stringent pricing has led to fewer new drug launches and longer waits for approvals. Patients suffer most: restricted access to novel therapies, as companies prioritize markets without such caps. The president's own COVID-19 vaccine triumphs, accelerated by Operation Warp Speed, underscore how U.S. innovation thrives without artificial price anchors.
Moreover, MFN doesn't address the real culprits behind high drug costs: opaque pharmacy benefit managers (and the recently passed PBM reform is a nice win), hospital markups, and a lack of competition in generics. It's a blunt instrument that punishes American ingenuity while letting foreign governments off the hook. If the goal is fairer trade, why not pressure allies like Germany or Canada to pay their share for R&D, rather than forcing U.S. prices down to their levels? The president's trade savvy could be better deployed here—negotiating international agreements that share the innovation burden, much like he did with intellectual property in USMCA. In fairness, the intent behind MFN is noble: easing the burden on seniors. But good intentions don't justify counterproductive policy.
The president's strength lies in bilateral deals that extract value without self-sabotage. By abandoning MFN for drugs and refocusing on holistic reforms, more PBM reform, using his HHS to clean-up how the 340-B drug program is being abused and like patent extensions for U.S.-first innovations or tariffs on foreign-subsidized generics, he could align his trade legacy with health care wins. Ultimately, the president's deal-making has revitalized American trade policy, making it a force for prosperity. Let's keep it that way by reserving those tactics for boardrooms and summits, not hospital rooms.
Our trading partners should feel the pressure—but not at the expense of the miracles developed in American labs.
Jack Kalavritinos is a health policy expert and public policy professional with experience in healthcare and regulatory affairs. He is the founder of JK Strategies.
